Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Leukemia, Neutropenia, Thrombocytopenia
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
83
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography
Procedure · Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
6
States / cities
Rochester, Minnesota • St Louis, Missouri • Hackensack, New Jersey + 3 more
Conditions
Lymphoma, Non-Hodgkin
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
21
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 17 more
Not listed Phase 1Phase 2 Interventional Results available

CNDO-109-AANK for AML in First Complete Remission (CR1)

NCT01520558
Conditions
Acute Myeloid Leukemia
Interventions
CNDO-109-AANK Cells
Biological
Lead sponsor
Coronado Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Minneapolis, Minnesota • St Louis, Missouri + 1 more
Conditions
Keratosis, Actinic
Interventions
MAL Cream, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
Conditions
Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
Interventions
Treatment guided by the PCR results, Treatment guided by the C&S results
Diagnostic Test
Lead sponsor
Doc Lab Inc
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Jose, California • Albany, Georgia • Evans, Georgia + 3 more
Conditions
Rectal Adenocarcinoma
Interventions
Capecitabine, Radiation Therapy, FOLFOX regimen
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Leukemia
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, cytarabine, fludarabine phosphate, methotrexate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Conditions
Ovarian Cancer
Interventions
Abagovomab, Placebo
Biological
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
22
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 17 more
Conditions
Leukemia
Interventions
aldesleukin, histamine dihydrochloride
Biological · Drug
Lead sponsor
Maxim Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 26 more
Conditions
SARS-CoV-2, COVID-19
Interventions
CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose), CV0601 mRNA COVID-19 Vaccine, Control vaccine, CV0801 mRNA COVID-19 Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
692 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Sacramento, California • Hollywood, Florida • Peoria, Illinois
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Interventions
Gilteritinib, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Gainesville, Florida • Jacksonville, Florida • Chicago, Illinois + 3 more
Conditions
Chronic Myeloid Leukemia
Interventions
Discontinuation of therapy
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
158
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 117 more
Conditions
Leukemia, Other, Cancer
Interventions
Gleevec and Arsenic Trioxide
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Conditions
TN ER-/PR-/HER2- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, ERany/PRany/HER2+ Breast Cancer
Interventions
Standard Trimodality Breast Imaging
Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Leukemia
Interventions
filgrastim
Biological
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission
Interventions
Ixazomib
Drug
Lead sponsor
Ehab L Atallah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Complete Remission
Interventions
Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total Marrow Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Duarte, California
Conditions
Breast Cancer
Interventions
Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
Behavioral · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Breast Cancer
Interventions
alpelisib, buparlisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Los Angeles, California + 16 more
Conditions
Triple-Negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab tirumotecan, Capecitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
89
States / cities
Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 74 more
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine
Drug
Lead sponsor
University of Florida
Other
Eligibility
61 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Pembrolizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas